{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T21:37:10Z","timestamp":1722893830041},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,1,3]],"date-time":"2012-01-03T00:00:00Z","timestamp":1325548800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1038\/tpj.2011.57","type":"journal-article","created":{"date-parts":[[2012,1,3]],"date-time":"2012-01-03T06:05:44Z","timestamp":1325570744000},"page":"197-204","source":"Crossref","is-referenced-by-count":16,"title":["Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population"],"prefix":"10.1038","volume":"13","author":[{"name":"Spanish Consortium of Pharmacogenetics Research in Schizophrenia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Almoguera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Riveiro-Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Lopez-Castroman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Dorado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Vaquero-Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Fernandez-Piqueras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Llerena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Baca-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Dal-R\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Ayuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,3]]},"reference":[{"key":"BFtpj201157_CR1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nrg1428","volume":"5","author":"UA Meyer","year":"2004","unstructured":"Meyer UA . Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004; 5: 669\u2013676.","journal-title":"Nat Rev Genet"},{"key":"BFtpj201157_CR2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209\u20131223.","journal-title":"N Engl J Med"},{"key":"BFtpj201157_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1176\/appi.psy.49.3.258","volume":"49","author":"J de Leon","year":"2008","unstructured":"de Leon J, Sandson NB, Cozza KL . A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part I. Psychosomatics 2008; 49: 258\u2013270.","journal-title":"Psychosomatics"},{"key":"BFtpj201157_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/tpj.2009.26","volume":"9","author":"P Gasso","year":"2009","unstructured":"Gasso P, Mas S, Bernardo M, Alvarez S, Parellada E, Lafuente A . A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J 2009; 9: 404\u2013410.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201157_CR5","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1365-2125.2003.02061.x","volume":"57","author":"N Yasui-Furukori","year":"2004","unstructured":"Yasui-Furukori N, Mihara K, Takahata T, Suzuki A, Nakagami T, De Vries R et al. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol 2004; 57: 569\u2013575.","journal-title":"Br J Clin Pharmacol"},{"key":"BFtpj201157_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/sj.tpj.6500474","volume":"8","author":"RC Smith","year":"2008","unstructured":"Smith RC, Segman RH, Golcer-Dubner T, Pavlov V, Lerer B . Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J 2008; 8: 228\u2013236.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201157_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/01.jcp.0000203196.65710.2b","volume":"26","author":"HY Lane","year":"2006","unstructured":"Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006; 26: 128\u2013134.","journal-title":"J Clin Psychopharmacol"},{"key":"BFtpj201157_CR8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/JCP.0b013e3180a76dc0","volume":"27","author":"H Mulder","year":"2007","unstructured":"Mulder H, Franke B, van der-Beek van der AA, Arends J, Wilmink FW, Scheffer H et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol 2007; 27: 338\u2013343.","journal-title":"J Clin Psychopharmacol"},{"key":"BFtpj201157_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1176\/appi.ajp.163.3.529","volume":"163","author":"T Lencz","year":"2006","unstructured":"Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry 2006; 163: 529\u2013531.","journal-title":"Am J Psychiatry"},{"key":"BFtpj201157_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/tpj.2009.24","volume":"9","author":"BA Fijal","year":"2009","unstructured":"Fijal BA, Kinon BJ, Kapur S, Stauffer VL, Conley RR, Jamal HH et al. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J 2009; 9: 311\u2013318.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201157_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/FPC.0b013e328311a917","volume":"19","author":"R Mossner","year":"2009","unstructured":"Mossner R, Schuhmacher A, Kuhn KU, Cvetanovska G, Rujescu D, Zill P et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet Genomics 2009; 19: 91\u201394.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201157_CR12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/sj.mp.4001944","volume":"12","author":"G Ruano","year":"2007","unstructured":"Ruano G, Goethe JW, Caley C, Woolley S, Holford TR, Kocherla M et al. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol Psychiatry 2007; 12: 474\u2013482.","journal-title":"Mol Psychiatry"},{"issue":"Suppl 20","key":"BFtpj201157_CR13","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (Suppl 20): 22\u201333; quiz 34-57.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj201157_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","volume":"334","author":"O Lingjaerde","year":"1987","unstructured":"Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K . The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1\u2013100.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"BFtpj201157_CR15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1373\/clinchem.2004.045203","volume":"51","author":"D Tejedor","year":"2005","unstructured":"Tejedor D, Castillo S, Mozas P, Jimenez E, Lopez M, Tejedor MT et al. Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 2005; 51: 1137\u20131144.","journal-title":"Clin Chem"},{"key":"BFtpj201157_CR16","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2217\/pgs.10.131","volume":"11","author":"B Almoguera","year":"2010","unstructured":"Almoguera B, Riveiro-Alvarez R, Gomez-Dominguez B, Lopez-Rodriguez R, Dorado P, Vaquero-Lorenzo C et al. Evaluating a newly developed pharmacogenetic array: screening in a Spanish population. Pharmacogenomics 2010; 11: 1619\u20131625.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201157_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2217\/pgs.09.165","volume":"11","author":"E Cuyas","year":"2010","unstructured":"Cuyas E, Olano-Martin E, Khymenets O, Hernandez L, Jofre-Monseny L, Grandoso L et al. Errors and reproducibility of DNA array-based detection of allelic variants in ADME genes: PHARMAchip. Pharmacogenomics 2010; 11: 257\u2013266.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201157_CR18","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/JCP.0b013e3181ee84c7","volume":"30","author":"J Novalbos","year":"2010","unstructured":"Novalbos J, Lopez-Rodriguez R, Roman M, Gallego-Sandin S, Ochoa D, Abad-Santos F . Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. J Clin Psychopharmacol 2010; 30: 504\u2013511.","journal-title":"J Clin Psychopharmacol"},{"key":"BFtpj201157_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4088\/JCP.v66n0103","volume":"66","author":"J de Leon","year":"2005","unstructured":"de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ . The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66: 15\u201327.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj201157_CR20","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1177\/0269881109104932","volume":"24","author":"J Du","year":"2009","unstructured":"Du J, Zhang A, Wang L, Xuan J, Yu L, Che R et al. Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients. J Psychopharmacol 2009; 24: 1115\u20131120.","journal-title":"J Psychopharmacol"},{"key":"BFtpj201157_CR21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.psychres.2007.06.006","volume":"160","author":"MR Kuzman","year":"2008","unstructured":"Kuzman MR, Medved V, Bozina N, Hotujac L, Sain I, Bilusic H . The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res 2008; 160: 308\u2013315.","journal-title":"Psychiatry Res"},{"key":"BFtpj201157_CR22","doi-asserted-by":"publisher","first-page":"987","DOI":"10.2217\/14622416.7.7.987","volume":"7","author":"Q Xing","year":"2006","unstructured":"Xing Q, Gao R, Li H, Feng G, Xu M, Duan S et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 2006; 7: 987\u2013993.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201157_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/hup.903","volume":"23","author":"PA Saiz","year":"2008","unstructured":"Saiz PA, Susce MT, Clark DA, Kerwin RW, Molero P, Arranz MJ et al. An investigation of the alpha1A-adrenergic receptor gene and antipsychotic-induced side-effects. Hum Psychopharmacol 2008; 23: 107\u2013114.","journal-title":"Hum Psychopharmacol"},{"key":"BFtpj201157_CR24","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/ejhg.2009.238","volume":"18","author":"M Xu","year":"2010","unstructured":"Xu M, Li S, Xing Q, Gao R, Feng G, Lin Z et al. Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study. Eur J Hum Genet 2010; 18: 707\u2013712.","journal-title":"Eur J Hum Genet"},{"key":"BFtpj201157_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2217\/14622416.10.3.385","volume":"10","author":"M Gupta","year":"2009","unstructured":"Gupta M, Bhatnagar P, Grover S, Kaur H, Baghel R, Bhasin Y et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 2009; 10: 385\u2013397.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201157_CR26","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.2217\/14622416.9.10.1437","volume":"9","author":"M Ikeda","year":"2008","unstructured":"Ikeda M, Yamanouchi Y, Kinoshita Y, Kitajima T, Yoshimura R, Hashimoto S et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008; 9: 1437\u20131443.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201157_CR27","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/tpj.2009.63","volume":"10","author":"CT Correia","year":"2010","unstructured":"Correia CT, Almeida JP, Santos PE, Sequeira AF, Marques CE, Miguel TS et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J 2010; 10: 418\u2013430.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201157_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/tpj.2008.6","volume":"9","author":"L Greenbaum","year":"2009","unstructured":"Greenbaum L, Smith RC, Rigbi A, Strous R, Teltsh O, Kanyas K et al. Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3\u2032-untranslated region. Pharmacogenomics J 2009; 9: 103\u2013110.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201157_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/hup.897","volume":"23","author":"B Kim","year":"2008","unstructured":"Kim B, Choi EY, Kim CY, Song K, Joo YH . Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum Psychopharmacol 2008; 23: 61\u201367.","journal-title":"Hum Psychopharmacol"},{"key":"BFtpj201157_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.psychres.2008.12.011","volume":"175","author":"J Vazquez-Bourgon","year":"2010","unstructured":"Vazquez-Bourgon J, Arranz MJ, Mata I, Pelayo-Teran JM, Perez-Iglesias R, Medina-Gonzalez L et al. Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry Res 2010; 175: 189\u2013194.","journal-title":"Psychiatry Res"},{"key":"BFtpj201157_CR31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","volume":"83","author":"A Gaedigk","year":"2008","unstructured":"Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS . The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83: 234\u2013242.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201157_CR32","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev.med.52.1.503","volume":"52","author":"S Kapur","year":"2001","unstructured":"Kapur S, Remington G . Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001; 52: 503\u2013517.","journal-title":"Annu Rev Med"},{"key":"BFtpj201157_CR33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.eurpsy.2005.12.005","volume":"21","author":"M Dossenbach","year":"2006","unstructured":"Dossenbach M, Dyachkova Y, Pirildar S, Anders M, Khalil A, Araszkiewicz A et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry 2006; 21: 251\u2013258.","journal-title":"Eur Psychiatry"},{"key":"BFtpj201157_CR34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/NDT.S4766","volume":"5","author":"H Liu-Seifert","year":"2009","unstructured":"Liu-Seifert H, Kinon BJ, Tennant CJ, Sniadecki J, Volavka J . Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatr Dis Treat 2009; 5: 47\u201354.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"BFtpj201157_CR35","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/sj.ijo.0802020","volume":"26","author":"DL Ellsworth","year":"2002","unstructured":"Ellsworth DL, Coady SA, Chen W, Srinivasan SR, Elkasabany A, Gustat J et al. Influence of the beta2-adrenergic receptor Arg16Gly polymorphism on longitudinal changes in obesity from childhood through young adulthood in a biracial cohort: the Bogalusa Heart Study. Int J Obes Relat Metab Disord 2002; 26: 928\u2013937.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BFtpj201157_CR36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ajhg.2009.06.005","volume":"85","author":"R Cagliani","year":"2009","unstructured":"Cagliani R, Fumagalli M, Pozzoli U, Riva S, Comi GP, Torri F et al. Diverse evolutionary histories for beta-adrenoreceptor genes in humans. Am J Hum Genet 2009; 85: 64\u201375.","journal-title":"Am J Hum Genet"},{"key":"BFtpj201157_CR37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrg2751","volume":"11","author":"AK Daly","year":"2010","unstructured":"Daly AK . Genome-wide association studies in pharmacogenomics. Nat Rev Genet 2010; 11: 241\u2013246.","journal-title":"Nat Rev Genet"},{"key":"BFtpj201157_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajmg.b.20045","volume":"124B","author":"G Szekeres","year":"2004","unstructured":"Szekeres G, Keri S, Juhasz A, Rimanoczy A, Szendi I, Czimmer C et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 124B: 1\u20135.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"BFtpj201157_CR39","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/sj.npp.1301418","volume":"33","author":"J Xuan","year":"2008","unstructured":"Xuan J, Zhao X, He G, Yu L, Wang L, Tang W et al. Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study. Neuropsychopharmacology 2008; 33: 305\u2013311.","journal-title":"Neuropsychopharmacology"},{"key":"BFtpj201157_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0074-7742(10)93001-8","volume":"93","author":"I Gvilia","year":"2010","unstructured":"Gvilia I . Underlying brain mechanisms that regulate sleep-wakefulness cycles. International review of neurobiology 2010; 93: 1\u201321.","journal-title":"International review of neurobiology"},{"key":"BFtpj201157_CR41","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00213-006-0622-x","volume":"190","author":"A Gunes","year":"2007","unstructured":"Gunes A, Scordo MG, Jaanson P, Dahl ML . Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology 2007; 190: 479\u2013484.","journal-title":"Psychopharmacology"},{"key":"BFtpj201157_CR42","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0006-8993(97)01078-0","volume":"779","author":"M Suzuki","year":"1998","unstructured":"Suzuki M, Hurd YL, Sokoloff P, Schwartz JC, Sedvall G . D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res 1998; 779: 58\u201374.","journal-title":"Brain Res"},{"key":"BFtpj201157_CR43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/BF01281155","volume":"102","author":"T Kling-Petersen","year":"1995","unstructured":"Kling-Petersen T, Ljung E, Svensson K . Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain. J Neural Transm Gen Sect 1995; 102: 209\u2013220.","journal-title":"J Neural Transm Gen Sect"},{"key":"BFtpj201157_CR44","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1006\/bbrc.1996.1296","volume":"225","author":"K Lundstrom","year":"1996","unstructured":"Lundstrom K, Turpin MP . Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 1996; 225: 1068\u20131072.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFtpj201157_CR45","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1093\/hmg\/11.20.2517","volume":"11","author":"VS Basile","year":"2002","unstructured":"Basile VS, Masellis M, Potkin SG, Kennedy JL . Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 2002; 11: 2517\u20132530.","journal-title":"Hum Mol Genet"},{"key":"BFtpj201157_CR46","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.metabol.2009.11.007","volume":"59","author":"J Bah","year":"2010","unstructured":"Bah J, Westberg L, Baghaei F, Henningsson S, Rosmond R, Melke J et al. Further exploration of the possible influence of polymorphisms in HTR2C and 5HTT on body weight. Metabolism 2010; 59: 1156\u20131163.","journal-title":"Metabolism"},{"key":"BFtpj201157_CR47","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/0269881104042618","volume":"18","author":"A Llerena","year":"2004","unstructured":"Llerena A, Berecz R, Dorado P, de la Rubia A . QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J Psychopharmacol 2004; 18: 189\u2013193.","journal-title":"J Psychopharmacol"},{"key":"BFtpj201157_CR48","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1017\/S1461145704004390","volume":"7","author":"JS Wang","year":"2004","unstructured":"Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL . The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 2004; 7: 415\u2013419.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFtpj201157_CR49","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/FTD.0b013e3181858ca9","volume":"30","author":"A Gunes","year":"2008","unstructured":"Gunes A, Spina E, Dahl ML, Scordo MG . ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit 2008; 30: 628\u2013633.","journal-title":"Ther Drug Monit"},{"key":"BFtpj201157_CR50","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0024-3205(02)01680-6","volume":"71","author":"DW Boulton","year":"2002","unstructured":"Boulton DW, DeVane CL, Liston HL, Markowitz JS . In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002; 71: 163\u2013169.","journal-title":"Life Sci"},{"key":"BFtpj201157_CR51","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473\u20133478.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/tpj201157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/tpj201157","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/tpj201157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:47:17Z","timestamp":1684608437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,3]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["BFtpj201157"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2011.57","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"type":"print","value":"1470-269X"},{"type":"electronic","value":"1473-1150"}],"subject":[],"published":{"date-parts":[[2012,1,3]]}}}